These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7516976)

  • 1. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease.
    Silver RI; Wiley EL; Davis DL; Thigpen AE; Russell DW; McConnell JD
    J Urol; 1994 Aug; 152(2 Pt 1):433-7. PubMed ID: 7516976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
    Thigpen AE; Silver RI; Guileyardo JM; Casey ML; McConnell JD; Russell DW
    J Clin Invest; 1993 Aug; 92(2):903-10. PubMed ID: 7688765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell type specific expression of steroid 5 alpha-reductase 2.
    Silver RI; Wiley EL; Thigpen AE; Guileyardo JM; McConnell JD; Russell DW
    J Urol; 1994 Aug; 152(2 Pt 1):438-42. PubMed ID: 8015089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate.
    Levine AC; Wang JP; Ren M; Eliashvili E; Russell DW; Kirschenbaum A
    J Clin Endocrinol Metab; 1996 Jan; 81(1):384-9. PubMed ID: 8550782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
    Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
    Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
    Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
    Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase.
    Bayne CW; Donnelly F; Chapman K; Bollina P; Buck C; Habib F
    J Clin Endocrinol Metab; 1998 Jan; 83(1):206-13. PubMed ID: 9435443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue.
    Bjelfman C; Söderström TG; Brekkan E; Norlén BJ; Egevad L; Unge T; Andersson S; Rane A
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2210-4. PubMed ID: 9215296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.
    De Marzo AM; Meeker AK; Epstein JI; Coffey DS
    Am J Pathol; 1998 Sep; 153(3):911-9. PubMed ID: 9736039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
    Bechis SK; Otsetov AG; Ge R; Wang Z; Vangel MG; Wu CL; Tabatabaei S; Olumi AF
    J Urol; 2015 Oct; 194(4):1031-7. PubMed ID: 25916673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro.
    Smith CM; Ballard SA; Worman N; Buettner R; Masters JR
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1361-6. PubMed ID: 8636334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metachromasia in the human prostate: a histochemical difference between benign prostatic hyperplasia and prostatic carcinoma.
    Arcadi JA
    J Urol; 1988 Feb; 139(2):315-7. PubMed ID: 2448498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture.
    Berthaut I; Mestayer C; Portois MC; Cussenot O; Mowszowicz I
    Prostate; 1997 Aug; 32(3):155-63. PubMed ID: 9254894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of human androgens and prostatic diseases.
    Novelli G; Margiotti K; Sangiuolo F; Reichardt JK
    Pharmacogenomics; 2001 Feb; 2(1):65-72. PubMed ID: 11258198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
    Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
    Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
    Anderson ML
    J Herb Pharmacother; 2005; 5(1):17-26. PubMed ID: 16093232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.